Market Overview

Exagen Diagnostics to Present at The Piper Jaffray 30th Annual Heathcare Conference

Share:

ALBUQUERQUE, NM and SAN DIEGO, CA, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Exagen Diagnostics, a leader in autoimmune life sciences, today announced that it will present at the Piper Jaffray 30th Annual Healthcare Conference, which is being held Nov. 27-29 at the Lotte New York Palace in New York.

Invest in IPO shares before the stock hits the market with ClickIPO. Check it out here

0_medium_Exagen_LogolargeJPEG.jpg



Ron Rocca, President and CEO, will present an overview of the patented cell-bound complement activation products (CB-CAPs) technology and other recent advances for the AVISE® brand of testing on Wednesday, November 28 at 10:50 a.m. ET. 

About Exagen Diagnostics
Exagen Diagnostics is a commercial stage life sciences company that is patient focused, and discovery driven. Exagen serves patients and healthcare providers across the U.S. in the diagnosis, prognosis, and management of lupus, rheumatoid arthritis, and other autoimmune conditions. By leveraging our patented and validated CB-CAPs technology we can help get to the real cause of a patient's symptoms and guide their journey to improved health. For more information visit, www.exagen.com or follow us on Facebook, Twitter, YouTube, LinkedIn, or Instagram.

 

Investor Contact: 
Kamal Adawi
Chief Financial Officer of Exagen Diagnostics, Inc.
760.477.5514
IR@exagen.com

Kamal Adawi
Exagen Diagnostics, Inc.
760.477.5514
IR@exagen.com

View Comments and Join the Discussion!